Jacobs Levy Equity Management’s Amicus Therapeutics FOLD Stock Holding History

Jacobs Levy Equity Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,675,373	Closed	-$19.4M	–	1024
2021 Q4	$19.4M	Sell	1,675,373 -134,419	-7%	-$1.5M	0.13%	191
2021 Q3	$17.3M	Buy	1,809,792 +84,264	+5%	+$862K	0.12%	207
2021 Q2	$16.6M	Buy	1,725,528 +1,467,313	+568%	+$14.3M	0.11%	219
2021 Q1	$2.55M	Buy	+258,215	New	+$4M	0.02%	547
2020 Q1	–	Sell	-181,176	Closed	-$1.76M	–	1035
2019 Q4	$1.76M	Buy	181,176 +162,076	+849%	+$1.48M	0.02%	569
2019 Q3	$153K	Buy	19,100 +1,900	+11%	+$20.6K	﹤0.01%	866
2019 Q2	$215K	Buy	+17,200	New	+$218K	﹤0.01%	868
2018 Q4	–	Sell	-74,724	Closed	-$903K	–	1011
2018 Q3	$903K	Buy	74,724 +21,624	+41%	+$302K	0.01%	666
2018 Q2	$829K	Buy	+53,100	New	+$803K	0.01%	705
2014 Q4	–	Sell	-55,885	Closed	-$333K	–	852
2014 Q3	$333K	Sell	55,885 -10,515	-16%	-$55.1K	0.01%	659
2014 Q2	$222K	Buy	+66,400	New	+$156K	﹤0.01%	751
2014 Q1	–	Sell	-28,912	Closed	-$68K	–	929
2013 Q4	$68K	Sell	28,912 -106,134	-79%	-$233K	﹤0.01%	918
2013 Q3	$313K	Buy	+135,046	New	+$339K	0.01%	785

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management's FOLD Position: Q1 2022 in Review

Jacobs Levy Equity Management sold out of Amicus Therapeutics (FOLD) in Q1 2022, closing a stake of 1,675,373 shares — an estimated $19.4M sold.

Jacobs Levy Equity Management first reported a position in FOLD in Q3 2013 and held it in 13 quarters. The position peaked at $19.4M in Q4 2021. 217 funds tracked by Wall St. Rank hold FOLD as of Q1 2022.

Jacobs Levy Equity Management reported no remaining Amicus Therapeutics position as of Q1 2022 after selling out during the quarter.
Jacobs Levy Equity Management sold 1,675,373 Amicus Therapeutics shares in Q1 2022, an estimated $19.4M.
Jacobs Levy Equity Management first reported a position in Amicus Therapeutics in Q3 2013 and held it in 13 quarters.
Jacobs Levy Equity Management's Amicus Therapeutics position peaked at $19.4M in Q4 2021.
217 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2022, filed 16 May 2022.